Today we’re announcing the close of our $350M Series A, bringing Lila’s total capital raised to $550M. We’re using this financing to accelerate the buildout of our AI Science Factories and bring our scientific superintelligence platform to customers working on the world’s hardest problems. Lila Sciences emerged from two years in stealth in March with a singular mission: build scientific superintelligence to solve humankind’s greatest challenges. That requires sleeves‑roll

Trial initiation follows the recent approval of IBTROZI™ (taletrectinib) for locally advanced or metastatic ROS1-positive non-small cell...

Flagship Pioneering’s Lila Sciences has landed a substantial $235 million series A as it looks to exceed the current limits of the drug...

Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I...

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in...

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without...

Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high,...

Boston, MA – May 27, 2025 – Indigo today announced that Microsoft has committed to purchase 60,000 soil carbon credits from the company’s...

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development...